Sugi Predict

Sugi Predict / Compounds / SCHEMBL30895121

SCHEMBL30895121

SCHEMBL30895121

[2H]C([2H])([2H])Oc1c(NC(=O)OC(C)(C)C)ccc2cnn(C3CC3)c12

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 1/20 0.36
▸ DYRK1A Q13627 1/20 0.36
▸ GPR119 Q8TDV5 2/20 0.35
▸ DGAT1 O75907 1/20 0.34
▸ METAP1 P53582 1/20 0.34
▸ JAK1 P23458 5/20 0.33
▸ JAK2 O60674 2/20 0.33
▸ OPRM1 P35372 1/20 0.33
▸ OPRD1 P41143 1/20 0.33
▸ OGFRL1 Q5TC84 1/20 0.33
▸ BRAF P15056 1/20 0.33
▸ BCL2 P10415 1/20 0.33
▸ PIK3CA P42336 1/20 0.32
▸ MTOR P42345 1/20 0.32
▸ PRKDC P78527 1/20 0.32
▸ CHRM1 P11229 1/20 0.32
▸ MAPKAPK2 P49137 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ NR3C1 P04150 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25753440 0.93 GSK3B (0.38) GSK3BDYRK1AGPR119DGAT1METAP1
SCHEMBL30895047 0.86 MAPK1 (0.39) GSK3BDYRK1APIK3CAMTORNR3C1
SCHEMBL25753091 0.86 MAPK1 (0.39) GSK3BDYRK1APIK3CAMTORNR3C1
SCHEMBL30895051 0.82 PIK3CD (0.39) GSK3BDYRK1AMETAP1PIK3CAMTOR
SCHEMBL30895054 0.82 MAPK1 (0.36) GSK3BDYRK1AMETAP1MAPKAPK2
SCHEMBL30895059 0.81 GSK3B (0.34) GSK3BDYRK1AMETAP1MAPKAPK2
SCHEMBL31017447 0.78 GSK3B (0.36) GSK3BDYRK1ADGAT1METAP1PIK3CA
SCHEMBL30895136 0.78 GSK3B (0.36) GSK3BDYRK1ADGAT1METAP1PIK3CA
SCHEMBL30860940 0.78 RXRA (0.38) GSK3BDYRK1ADGAT1OPRM1OPRD1
SCHEMBL27199485 0.78 BRD4 (0.38) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO LTD (CN) 2025-04-10 — — US disclosed
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-10-29 — — US disclosed
CN-118401516-A TYK2 inhibitors, compositions and methods thereof 凌科药业(杭州)有限公司 2024-07-26 — — CN disclosed
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 GSK3B 117/4885DYRK1A 56/4885GPR119 1654/4885
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 GSK3B 117/4885DYRK1A 56/4885GPR119 1654/4885
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof TYK2, JAK2, JAK1 GSK3B 117/4885DYRK1A 56/4885GPR119 1654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.